Immunomodulating Drugs | List of Frontiers open access articles

Mini Review

Published on 15 Feb 2021

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

in Cancer Immunity and Immunotherapy

Anne Marit Sponaas
Anders Waage
Esten N. Vandsemb
Kristine Misund
Magne Børset
Anders Sundan
Tobias Schmidt Slørdahl
Therese Standal

Frontiers in Immunology

doi 10.3389/fimmu.2021.636375

5,058 views
5 citations

Review

Published on 03 Jan 2013

Novel immune modulators used in hematology: impact on NK cells

in NK and Innate Lymphoid Cell Biology

Stephanie Krieg
Evelyn Ullrich

Frontiers in Immunology

doi 10.3389/fimmu.2012.00388

10,500 views
45 citations

Review

Published on 10 Aug 2022

Boosting regulatory T cell function for the treatment of autoimmune diseases – That’s only half the battle!

in Vaccines and Molecular Therapeutics

Janine Schlöder
Fatemeh Shahneh
Franz-Joseph Schneider
Björn Wieschendorf

Frontiers in Immunology

doi 10.3389/fimmu.2022.973813

21,129 views
56 citations

Original Research

Published on 19 Jul 2021

Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis

in Cardiovascular Therapeutics

Arduino A. Mangoni
Richard J. Woodman
Matteo Piga
Alberto Cauli
Anna Laura Fedele
Elisa Gremese
Gian Luca Erre
The EDRA Study Group
Floriana Castagna
Marco Piras

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2021.681327

3,367 views
12 citations

Original Research

Published on 17 Dec 2021

Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)

in Skin Cancer

Marco Rastrelli
Paolo Del Fiore
Irene Russo
Jacopo Tartaglia
Alessandro Dal Monico
Rocco Cappellesso
Lorenzo Nicolè
Luisa Piccin
Alessio Fabozzi
Bernardo Biffoli

Frontiers in Oncology

doi 10.3389/fonc.2021.737842

4,454 views
11 citations

Review

Published on 29 Jul 2020

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality

in Genitourinary Oncology

Xiaohan Zhou
Wanting Hou
Ling Gao
Lin Shui
Cheng Yi
Hong Zhu

Frontiers in Oncology

doi 10.3389/fonc.2020.01321

8,720 views
31 citations

Original Research

Published on 27 May 2022

Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After

in Radiation Oncology

Susan Woody
Aparna Hegde
Hyder Arastu
M. Sean Peach
Nitika Sharma
Paul Walker
Andrew W. Ju

Frontiers in Oncology

doi 10.3389/fonc.2022.785350

4,229 views
19 citations

Articles

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

Novel immune modulators used in hematology: impact on NK cells

Boosting regulatory T cell function for the treatment of autoimmune diseases – That’s only half the battle!

Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis

Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality

Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After